PBF-677 / Palobiofarma, Ligand - LARVOL DELTA

ADENOIBD: Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients (clinicaltrials.gov) - P2a; N=34; Completed; Sponsor: Palobiofarma SL; Recruiting ➔ Completed; N=50 ➔ 34; Trial completion date: Oct 2021 ➔ May 2021; Trial primary completion date: Aug 2021 ➔ May 2021

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

ADENOIBD: Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients (clinicaltrials.gov) - P2a; N=50; Recruiting; Sponsor: Palobiofarma SL; Trial completion date: Dec 2020 ➔ Oct 2021; Trial primary completion date: Jun 2020 ➔ Aug 2021

Clinical • Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis